3 assets in Acute Myeloid Leukemia And Myelodysplastic Syndromes Related To Alkylating Agent

Therapeutic assets addressing Acute Myeloid Leukemia And Myelodysplastic Syndromes Related To Alkylating Agent, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Cytarabine Acute Myeloid Leukemia And Myelodysplastic Syndromes Related To Alkylating Agent	National Cancer Institute (NCI)	P2	BB (64)
Decitabine Acute Myeloid Leukemia And Myelodysplastic Syndromes Related To Alkylating Agent	Roswell Park Cancer Institute	P2	B (60)
Daunomycin Acute Myeloid Leukemia And Myelodysplastic Syndromes Related To Alkylating Agent	National Cancer Institute (NCI)	P2	CCC (53)